PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

Novo Nordisk Presents Results of Concizumab in P-III (explorer7) Study for the Treatment of Haemophilia A or B at ISTH 2022

Novo Nordisk Presents Results of Concizumab in P-III (explorer7) Study for the Treatment of Haemophilia A or B at ISTH 2022

July 11, 2022

Kyle Forcier, Senior Director of Life Sciences Product Marketing at Model N Shares Insights on How Model N Helps Life Sciences Companies Navigate Greater Compliance Pressure

Kyle Forcier, Senior Director of Life Sciences Product Marketing at Model N Shares Insights on How Model N Helps Life Sciences Com...

July 11, 2022

Anthos’ Abelacimab Receives the US FDA’s Fast Track Designation for the Treatment of Thrombosis Associated with Cancer

Anthos’ Abelacimab Receives the US FDA’s Fast Track Designation for the Treatment of Thrombosis Associated with Cancer

July 11, 2022

Telix Reports the Completion of Patient Enrollment in P-III (ZIRCON) Study of TLX250-CDx for the Treatment of Clear Cell Renal Cell Cancer

Telix Reports the Completion of Patient Enrollment in P-III (ZIRCON) Study of TLX250-CDx for the Treatment of Clear Cell Renal Cel...

July 11, 2022

Sanofi and Sobi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) Study for the Treatment of Severe Hemophilia A

Sanofi and Sobi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) Study for the Treatment of Severe Hemophilia A

July 11, 2022

Horizon’s Krystexxa (pegloticase) Receives the US FDA’s Approval and Expanding the Labeling for the Treatment of Uncontrolled Gout

Horizon’s Krystexxa (pegloticase) Receives the US FDA’s Approval and Expanding the Labeling for the Treatment of Uncontrolled Gout

July 11, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us